Renata PLC launches the first generic version of Cabergoline 0.5 mg in Australia
Renata PLC, a leading pharmaceutical manufacturer in Bangladesh, has become the first company to launch a generic version of Cabergoline 0.5 mg in Australia. The medicine is an effective treatment for hyperprolactinemia and Parkinson's disease.
The first shipment has been executed and has already reached Australia. The distribution and commercialisation of Cabergoline, marketed under the brand name Dostamine, will be facilitated in Australia through Renata's partner, Nova Pharmaceuticals Australasia Pty Ltd.
"This milestone reflects Renata's commitment to expanding its product offerings in the Australia and New Zealand markets, highlighting our expertise in developing and delivering low-dose, high-potency complex products," stated Renata PLC.
Keep updated, follow The Business Standard's Google news channel
Cabergoline 0.5 mg is manufactured at Renata's facility, which is approved by both the TGA and the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The manufacturing plant, located in Mirpur, Dhaka, adheres to stringent quality control measures to meet global market demands.
In addition to its recent approval in Australia, Renata PLC has also secured regulatory approvals for Cabergoline in the UK and European Union, further solidifying its presence in international markets. Globally, the market for Cabergoline is substantial, with increasing demand fuelled by its efficacy in treating hyperprolactinemia and Parkinson's disease. In Bangladesh, Cabergoline is marketed under the local brand name Cabolin, ensuring patients have access to effective treatments for their medical needs.
This demonstrates Renata PLC's dedication to enhancing patient care and addressing critical healthcare challenges through its innovative product offerings and international collaborations.
